MX2024011603A - Forma de sal cristalina de un inhibidor de shp2. - Google Patents
Forma de sal cristalina de un inhibidor de shp2.Info
- Publication number
- MX2024011603A MX2024011603A MX2024011603A MX2024011603A MX2024011603A MX 2024011603 A MX2024011603 A MX 2024011603A MX 2024011603 A MX2024011603 A MX 2024011603A MX 2024011603 A MX2024011603 A MX 2024011603A MX 2024011603 A MX2024011603 A MX 2024011603A
- Authority
- MX
- Mexico
- Prior art keywords
- salt form
- crystalline salt
- shp2 inhibitor
- crystalline form
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323005P | 2022-03-23 | 2022-03-23 | |
| PCT/IB2023/052709 WO2023180898A1 (en) | 2022-03-23 | 2023-03-20 | Crystalline salt form of a shp2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024011603A true MX2024011603A (es) | 2024-09-30 |
Family
ID=85724850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024011603A MX2024011603A (es) | 2022-03-23 | 2023-03-20 | Forma de sal cristalina de un inhibidor de shp2. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250214966A1 (enExample) |
| EP (1) | EP4496629A1 (enExample) |
| JP (1) | JP2025509818A (enExample) |
| KR (1) | KR20240163705A (enExample) |
| CN (1) | CN119095836A (enExample) |
| AR (1) | AR128847A1 (enExample) |
| AU (1) | AU2023238523B2 (enExample) |
| CA (1) | CA3256136A1 (enExample) |
| MX (1) | MX2024011603A (enExample) |
| TW (1) | TW202346282A (enExample) |
| WO (1) | WO2023180898A1 (enExample) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021002880A (es) | 2018-09-14 | 2021-06-04 | Unilever Ip Holdings B V | Evaluacion de la eficacia de composiciones cosmeticas que no se deben enjuagar para proteger la piel de los contaminantes. |
| IL320682A (en) * | 2019-04-02 | 2025-07-01 | Array Biopharma Inc | Protein tyrosine phosphatase inhibitors |
-
2023
- 2023-03-20 KR KR1020247034661A patent/KR20240163705A/ko active Pending
- 2023-03-20 CN CN202380027478.0A patent/CN119095836A/zh active Pending
- 2023-03-20 MX MX2024011603A patent/MX2024011603A/es unknown
- 2023-03-20 EP EP23712623.0A patent/EP4496629A1/en active Pending
- 2023-03-20 WO PCT/IB2023/052709 patent/WO2023180898A1/en not_active Ceased
- 2023-03-20 AU AU2023238523A patent/AU2023238523B2/en active Active
- 2023-03-20 CA CA3256136A patent/CA3256136A1/en active Pending
- 2023-03-20 US US18/848,662 patent/US20250214966A1/en active Pending
- 2023-03-20 JP JP2024555324A patent/JP2025509818A/ja active Pending
- 2023-03-22 AR ARP230100698A patent/AR128847A1/es unknown
- 2023-03-22 TW TW112110698A patent/TW202346282A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025509818A (ja) | 2025-04-11 |
| TW202346282A (zh) | 2023-12-01 |
| WO2023180898A1 (en) | 2023-09-28 |
| US20250214966A1 (en) | 2025-07-03 |
| AR128847A1 (es) | 2024-06-19 |
| CA3256136A1 (en) | 2023-09-28 |
| CN119095836A (zh) | 2024-12-06 |
| KR20240163705A (ko) | 2024-11-19 |
| AU2023238523B2 (en) | 2025-10-30 |
| AU2023238523A1 (en) | 2024-08-22 |
| EP4496629A1 (en) | 2025-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023019479A2 (pt) | Forma cristalina de um inibidor de shp2 | |
| CO2023012682A2 (es) | 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek | |
| PY1932509A (es) | Inhibidores de cinasa dependientes de ciclina | |
| CO2021017504A2 (es) | Derivados de benzisoxazol sulfonamida | |
| CL2019000368A1 (es) | Inhibidores de cdk2/4/6. | |
| GT201200242A (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| CL2018003577A1 (es) | Piridina substituida como inhibidor de dnmt1. | |
| CL2009000780A1 (es) | Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k. | |
| ECSP099803A (es) | Derivados de bencimidazol | |
| ECSP055867A (es) | Derivados de pirrolopirimidina | |
| UY32582A (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero | |
| GT200600517A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| ECSP17026210A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| CO6630133A2 (es) | Compuestos de pirazol -4-il heterociclil -carboxamida y métodos de uso | |
| HN2005000212A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| TW200942536A (en) | PIM kinase inhibitors and methods of their use | |
| UY33328A (es) | "5,7-SUSTITUIDO-IMIDAZOL[1,2-c]PIRIMIDINAS" | |
| CL2022001337A1 (es) | Derivados de piridopirimidinona como antagonistas de ahr | |
| DOP2025000216A (es) | Derivados de fenilpiperidina como inhibidores de la glutaminil-péptido ciclotransferasa y proteína similar a glutaminil-péptido ciclotransferasa | |
| UY31775A (es) | Compuestos heterocíclicos como inhibidores de mek | |
| CL2025001366A1 (es) | Derivados de fenilpiperidina como inhibidores de la glutaminil-péptido ciclotransferasa y proteína similar a glutaminil-péptido ciclotransferasa | |
| UY28894A1 (es) | Derivados de pirimidina para tratar el crecimiento celular anómalo | |
| AR128847A1 (es) | Forma de sal cristalina de un inhibidor de shp2 | |
| CL2024003797A1 (es) | Compuestos derivados de 2-oxo-1,2-dihidroquinolina que degradan bcl6, composición y uso para tratar el cancer. | |
| AR133442A1 (es) | Derivados de piperidinilpiridinilcarbonitrilo como inhibidores de la glutamil-péptido ciclotransferasa y proteína similar a glutaminil-péptido ciclotransferasa |